AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Thornburg Investment Management Inc.

Thornburg Investment Management Inc. cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 11.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 508,872 shares of the company's stock after selling 63,208 shares during the period. Thornburg Investment Management Inc.'s holdings in AstraZeneca were worth $34,358,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Sanders Capital LLC acquired a new stake in shares of AstraZeneca during the third quarter worth approximately $715,198,000. Manning & Napier Group LLC raised its stake in AstraZeneca by 281.2% during the fourth quarter. Manning & Napier Group LLC now owns 2,779,212 shares of the company's stock valued at $187,180,000 after buying an additional 2,050,064 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of AstraZeneca by 5.2% in the 3rd quarter. Jennison Associates LLC now owns 22,946,504 shares of the company's stock valued at $1,553,937,000 after acquiring an additional 1,139,295 shares during the last quarter. abrdn plc raised its holdings in shares of AstraZeneca by 346.3% during the fourth quarter. abrdn plc now owns 1,420,876 shares of the company's stock worth $95,696,000 after purchasing an additional 1,102,490 shares during the period. Finally, Barclays PLC lifted its holdings in AstraZeneca by 317.4% in the third quarter. Barclays PLC now owns 1,242,431 shares of the company's stock worth $84,136,000 after acquiring an additional 944,765 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.5 %

Shares of AZN traded down $0.39 during mid-day trading on Tuesday, reaching $77.04. The company's stock had a trading volume of 4,115,924 shares, compared to its average volume of 6,223,467. The company has a market cap of $238.86 billion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 1.40 and a beta of 0.47. The business has a fifty day moving average of $69.78 and a 200 day moving average of $66.89. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $77.93.

Analyst Ratings Changes

AZN has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on AstraZeneca in a research report on Tuesday, January 23rd. They set an "overweight" rating for the company. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a research report on Tuesday, April 16th. Finally, BMO Capital Markets raised their price objective on AstraZeneca from $80.00 to $82.00 and gave the stock an "outperform" rating in a research note on Friday, April 26th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, AstraZeneca has an average rating of "Moderate Buy" and an average target price of $81.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.